Does fructose consumption contribute to non-alcoholic fatty liver disease?

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 6, 2012, Pages 554-560

  Tappy, Luc ^a,b   Lê, Kim Anne ^c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b University of Lausanne Medical Center   (Switzerland)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FRUCTOSE; GLUCOSE; GLYCOGEN; HEXOSE; LACTIC ACID; SUCROSE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

BODY COMPOSITION; CALORIC INTAKE; CARBOHYDRATE INTAKE; DIABETES MELLITUS; DYSLIPIDEMIA; FRUCTOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIPOGENESIS; LIVER CIRRHOSIS; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; SHORT SURVEY; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; DIET; DISEASE MODELS, ANIMAL; FATTY LIVER; FRUCTOSE; HUMANS; INFLAMMATION;

EID: 84870389895     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.06.005     Document Type: Short Survey

References (67)

1. Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011, 34:274-285.
2. Malaguarnera M., Di Rosa M., Nicoletti F., Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) 2009, 87:679-695.
3. Bhala N., Angulo P., van der Poorten D., et al. The natural history of non-alcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
4. Maheshwari A., Thuluvath P.J. Cryptogenic cirrhosis and NAFLD: are they related?. Am J Gastroenterol 2006, 101:664-668.
5. Allard J.P. Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol 2002, 16:783-795.
6. Zivkovic A.M., German J.B., Sanyal A.J. Comparative review of diets for the metabolic syndrome: implications for non-alcoholic fatty liver disease. Am J Clin Nutr 2007, 86:285-300.
7. Bray G.A. Fructose: should we worry?. IJO 2008, 32(Suppl. 7):S127-S131.
8. Lustig R.H. Fructose: metabolic, hedonic, and societal parallels with ethanol. JADA 2010, 110:1307-1321.
9. White J.S. Straight talk about high fructose corn syrup: what it is and what it ain't. Am J Clin Nutr 2008, 88:1716S-1721S.
10. Vos M.B., Kimmons J.E., Gillespie C., et al. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 2008, 10:160.
11. Marriott B.P., Olsho L., Hadden L., Connor P. Intake of added sugars and selected nutrients in the United States, National Health and Nutrition Examination Survey (NHANES) 2003-2006. Crit Rev Food Sci Nutr 2010, 50:228-258.
12. Diggle C.P., Shires M., McRae C., et al. Both isoforms of ketohexokinase are dispensable for normal growth and development. Physiological genomics 2010, 42A:235-243.
13. Rajas F., Bruni N., Montano S., et al. The glucose-6 phosphatase gene is expressed in human and rat small intestine: regulation of expression in fasted and diabetic rats. Gastroenterology 1999, 117:132-139.
14. Haidari M., Leung N., Mahbub F., et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance. Evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 2002, 277:31646-31655.
15. Mayes P.A. Intermediary metabolism of fructose. Am J Clin Nutr 1993, 58:754S-765S.
16. Van den Berghe G. Fructose: metabolism and short-term effects on carbohydrate and purine metabolic pathways. Prog Biochem Pharmacol 1986, 21:1-32.
17. Tappy L., Le K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiological reviews 2010, 90:23-46.
18. Bizeau M.E., Pagliassotti M.J. Hepatic adaptations to sucrose and fructose. Metabolism: clinical and experimental 2005, 54:1189-1201.
19. Pagliassotti M.J., Prach P.A., Koppenhafer T.A., Pan D.A. Changes in insulin action, triglycerides, and lipid composition during sucrose feeding in rats. Am J Physiol 1996, 271:R1319-R1326.
20. Nagata R., Nishio Y., Sekine O., et al. Single nucleotide polymorphism (-468 Gly to A) at the promoter region of SREBP-1c associates with genetic defect of fructose-induced hepatic lipogenesis [corrected]. J Biol Chem 2004, 279:29031-29042.
21. Horton T.J., Gayles E.C., Prach P.A., et al. Female rats do not develop sucrose-induced insulin resistance. Am J Physiol 1997, 272:R1571-R1576.
22. Chevalier M., Wiley J.H., Leveille G.A. The age-dependent response of serum triglycerides to dietary fructose. Proc Soc Exp Biol Med 1972, 139:220-222.
23. Yki-Jarvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance: human data. Curr Opin Clin Nutr Metab Care 2010, 13:709-714.
24. Bizeau M.E., Short C., Thresher J.S., et al. Increased pyruvate flux capacities account for diet-induced increases in gluconeogenesis in vitro. Am J Physiol Regul Integr Comp Physiol 2001, 281:R427-R433.
25. Davail S., Rideau N., Bernadet M.D., et al. Effects of dietary fructose on liver steatosis in overfed mule ducks. Horm Metab Res 2005, 37:32-35.
26. Sato A., Kawano H., Notsu T., et al. Antiobesity effect of eicosapentaenoic acid in high fat/high sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010, 59:2495-2504.
27. Bremer A.A., Stanhope K.L., Graham J.L., et al. Fructose-fed rhesus monkeys: a non-human primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Transl Sci 2011, 4:243-252.
28. Pichon L., Huneau J.F., Fromentin G., Tome D. A high protein, high fat, carbohydrate-free diet reduces energy intake, hepatic lipogenesis, and adiposity in rats. J Nutr 2006, 136:1256-1260.
29. Noguchi Y., Nishikata N., Shikata N., et al. Ketogenic essential amino acids modulate lipid synthetic pathways and prevent hepatic steatosis in mice. PLoS ONE 2010, 5:e12057.
30. Botezelli J.D., Mora R.F., Dalia R.A., et al. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet. Lipids Health Dis 2010, 9:116.
31. Arteel G.E. New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury. J Gastroenterol Hepatol 2008, 23(Suppl. 1):S54-S59.
32. Iimuro Y., Gallucci R.M., Luster M.I., et al. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997, 26:1530-1537.
33. Kanuri G., Spruss A., Wagnerberger S., et al. Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells. Lab Invest 2011, 91:885-895.
34. Kanuri G., Spruss A., Wagnerberger S., et al. Role of tumor necrosis factor alpha (TNF-alpha) in the onset of fructose-induced non-alcoholic fatty liver disease in mice. J Nutr Biochem 2011, 22:527-534.
35. Serino M., Luche E., Gres S., et al. Metabolic adaptation to a high fat diet is associated with a change in the gut microbiota. Gut 2012, 61:543-553.
36. Thuy S., Ladurner R., Volynets V., et al. Non-alcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008, 138:1452-1455.
37. Bergheim I., Weber S., Vos M., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008, 48:983-992.
38. Kohli R., Kirby M., Xanthakos S.A., et al. High fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and non-alcoholic steatohepatitis. Hepatology 2010, 52:934-944.
39. Pickens M.K., Ogata H., Soon R.K., et al. Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine-choline-deficient diet. Liver Int 2010, 30:1229-1239.
40. Lee O., Bruce W.R., Dong Q., et al. Fructose and carbonyl metabolites as endogenous toxins. Chem Biol Interact 2009, 178:332-339.
41. Yuen A., Laschinger C., Talior I., et al. Methylglyoxal-modified collagen promotes myofibroblast differentiation. Matrix Biol 2010, 29:537-548.
42. Mello T., Ceni E., Surrenti C., Galli A. Alcohol-induced hepatic fibrosis: role of acetaldehyde. Mol Aspects Med 2008, 29:17-21.
43. Le K.A., Faeh D., Stettler R., et al. A 4-week high fructose diet alters lipid metabolism without affecting insulin sensitivity or ectopic lipids in healthy humans. Am J Clin Nutr 2006, 84:1374-1379.
44. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009.
45. Stanhope K.L., Griffen S.C., Bair B.R., et al. Twenty-four-hour endocrine and metabolic profiles following consumption of high fructose corn syrup-, sucrose-, fructose-, and glucose-sweetened beverages with meals. Am J Clin Nutr 2008, 87:1194-1203.
46. Stanhope K.L., Bremer A.A., Medici V., et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab 2011, 96:E1596-E1605.
47. Aeberli I., Gerber P.A., Hochuli M., et al. Low to moderate sugar-sweetened beverage consumption impairs glucose and lipid metabolism and promotes inflammation in healthy young men: a randomized controlled trial. Am J Clin Nutr 2011, 94:479-485.
48. Aeberli I., Zimmermann M.B., Molinari L., et al. Fructose intake is a predictor of LDL particle size in overweight schoolchildren. Am J Clin Nutr 2007, 86:1174-1178.
49. Le K.A., Ith M., Kreis R., et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 2009, 89:1760-1765.
50. Faeh D., Minehira K., Schwarz J.M., et al. Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 2005, 54:1907-1913.
51. Silbernagel G., Machann J., Unmuth S., et al. Effects of 4-week very high fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br J Nutr 2011, 106:79-86.
52. Livesey G., Taylor R. Fructose consumption and consequences for glycation, plasma triacylglycerol, and body weight: meta-analyses and meta-regression models of intervention studies. Am J Clin Nutr 2008, 88:1419-1437.
53. Sievenpiper J.L., Carleton A.J., Chatha S., et al. Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. Diabetes Care 2009, 32:1930-1937.
54. Sobrecases H., Le K.A., Bortolotti M., et al. Effects of short-term overfeeding with fructose, fat and fructose plus fat on plasma and hepatic lipids in healthy men. Diabetes Metab 2010, 36:244-246.
55. Bortolotti M., Maiolo E., Corazza M., et al. Effects of a whey protein supplementation on intrahepatocellular lipids in obese female patients. Clin Nutr 2011, 30:494-498.
56. Bortolotti M., Kreis R., Debard C., et al. High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr 2009, 90:1002-1010.
57. Theytaz F., Noguchi Y., Eglis L., et al. Effects of a supplementation with essential amino acids on intrahepatic lipid concentrations during fructose overfeeding in humans. FASEB J 2012, 26:lb290. [Note abstract presented at the EB meeting 2012].
58. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48:993-999.
59. Assy N., Nasser G., Kamayse I., et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 2008, 22:811-816.
60. Abdelmalek M.F., Suzuki A., Guy C., et al. Increased fructose consumption is associated with fibrosis severity in patients with non-alcoholic fatty liver disease. Hepatology 2010, 51:1961-1971.
61. Romeo S., Kozlitina J., Xing C., et al. Genetic variation in PNPLA3 confers susceptibility to non-alcoholic fatty liver disease. NG 2008, 40:1461-1465.
62. Rotman Y., Koh C., Zmuda J.M., et al. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of non-alcoholic fatty liver disease. Hepatology 2010, 52:894-903.
63. Trepo E., Guyot E., Ganne-Carrie N., et al. PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology 2012, 55:1307-1308.
64. Davis J.N., Le K.A., Walker R.W., et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 2010, 92:1522-1527.
65. Duvnjak M., Barsic N., Tomasic V., Lerotic I. Genetic polymorphisms in non-alcoholic fatty liver disease: clues to pathogenesis and disease progression. World J Gastroenterol 2009, 15:6023-6027.
66. Fabbrini E., Mohammed B.S., Magkos F., et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with non-alcoholic fatty liver disease. Gastroenterology 2008, 134:424-431.
67. Korenblat K.M., Fabbrini E., Mohammed B.S., Klein S. Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 2008, 134:1369-1375.